

Zydus receives approval from Health Canada for Mesalamine suppositories

Ahmedabad, India, October 24, 2025

Zydus Lifesciences Limited (including its subsidiaries/ affiliates, hereafter referred to as “Zydus”) has received NOC (Notice of Compliance) from Health Canada for generic Mesalamine suppositories 1000 mg.

Mesalamine suppositories are indicated for the treatment of mildly to moderately active ulcerative proctitis.

ZDS - Mesalamine suppositories will be manufactured at Zydus Lifesciences Ltd. Changodar, Ahmedabad in Gujarat, India. Mesalamine suppositories had annual sales of 4.86 mn CAD (Canadian Dollars) in Canada (IQVIA MAT June 2025).

###



**PRESS
RELEASE**

For further information please contact :
The Corporate Communications Department

Zydus Lifesciences Limited
Regd. Office : 'Zydus Corporate Park',
Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar),
Nr. Vaishnodevi Circle, S. G. Highway, Ahmedabad 382
481, Gujarat, India. | Phone : +91-79-71800000,
+91-79-48040000 | website : www.zyduslife.com
CIN : L24230GJ1995PLC025878